Feb 23, 2026

How many people actually pay with Bitcoin? Real use cases revealed

How many people really pay with Bitcoin? Survey data, payment processors and country case studies reveal where BTC is used for rea...

Feb 23, 2026

Tether flashes Bitcoin bottom signal: Can BTC stage another 100% rally?

Bitcoin price more than doubled the last time Tether's crypto market capitalization dropped by $3 billion in two months, a signal...

Feb 23, 2026

Elliptic flags Russia-linked crypto platforms’ ongoing sanctions evasion

Bitpapa, Garantex and ABCeX were among the cryptocurrency exchanges linked to Russian-tied transactions circumventing Western evas...

Feb 23, 2026

Revolut confirms ex-employee threatened to leak KYC data for crypto ransom

A crypto trader said a former Revolut employee tried to extort him and contacted his relatives. Revolut confirmed an investigation...

Feb 23, 2026

Curve founder says DeFi must ditch token emissions for real revenue

Curve founder Michael Egorov told Cointelegraph that protocols cannot “live without real revenues flowing” as token incentives los...

Feb 23, 2026

CoinDesk 20 performance update: AAVE gains 1.7% while index trades lower over we...

Uniswap (UNI) joined Aave (AAVE) as a top performers, gaining 0.5% from Friday.

Feb 23, 2026

Domino’s Pizza (DPZ) Stock Rises on Strong Q4 Results and 14% Dividend Hike

TLDR U.S. same-store sales grew 3.7% in Q4, beating analyst estimates of 3.47% Revenue hit $1.54B, up 6.4% year-over-year and $20M...

Feb 23, 2026

Standard Chartered sticks to $2T stablecoin call but trims T-bill impact

Standard Chartered slashed its forecast for T-bill demand from stablecoins to $800 billion to $1 trillion by 2028, but maintained...

Feb 23, 2026

Missouri Advances Bitcoin Reserve Bill to House Committee in Policy Push

Missouri Bitcoin Reserve Bill Advances to House CommitteeThe post Missouri Advances Bitcoin Reserve Bill to House Committee in Po...

Feb 23, 2026

Novo Nordisk (NVO) Stock Drops 15% After CagriSema Fails to Beat Eli Lilly’s Zep...

TLDR Novo Nordisk stock fell 15% after CagriSema failed to prove non-inferiority to Eli Lilly’s tirzepatide in an 84-week trial. C...